c-Myc inhibitor 8

c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of KU-19-19, 253J, J82, Τ24, ΜΒΤ-2 and UM-UC-3 bladder cancer cell lines with IC₅₀s of 0.90, 1.11, 1.46, 0.98, 1.18 and 1.25 μM, respectively^[1].
c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of Α549, NCI-H460, MRC-5 and NCI-H23 hepatoma cell lines with IC₅₀s of 1.70, 1.90, 1.24 and 1.04 μM, respectively^[1].
c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of MDA-MB-231, SK-BR-3, HCC1954 and MDA-MB-468 breast cancer cell lines with IC₅₀s of 1.45, 1.38, 1.47 and 1.64 μM, respectively^[1].
c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of HL-60, U-937, Raji, Ramos (RAl), Daudi, Jurkat, MV-4-11 and MOLT-4 blood cancer cell lines with IC₅₀s of 1.95, 1.75, 1.12, 1.86, 1.25, 1.06, 1.50 and 1.66 μM, respectively^[1].
c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of ΜΙΑ PaCa-2 pancreatic cancer cell line with an IC₅₀ of 1.37 μM^[1].
c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of HCT 116, SW620, HCT-15, RKO, HCT-8 and DLD-I colorectal cancer cell lines with IC₅₀s of 1.19, 1.91, 1.32, 1.53, 1.69 and 0.80 μM, respectively^[1].
c-Myc inhibitor 8 (0-2 μM; 24 hours) inhibits cell viability of U-251 MG, U-138 MG, LOX-IMVI, SK-HEP-I and OVCAR-3 cancer cell lines with IC₅₀s of 1.17, 1.34, 1.09, 1.02 and 1.09 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.